REG - Iconic Labs PLC - Statement re CVA

Iconic LabsAnnouncement

12/09/2023 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230912:nRSL1540Ma&default-theme=true

RNS Number : 1540M  Iconic Labs PLC  12 September 2023

 

 

 12 September 2023

Iconic Labs PLC

 

("Iconic" or the "Company")

 

Allotment of Shares and Conclusion of CVA

 

Iconic Labs PLC (LSE: ICON) today announces that 83,256 ordinary shares of
£0.1 were allotted to the unsecured creditors (the "Unsecured Creditors") in
accordance with the Creditors Voluntary Arrangement (CVA) dated 22 September
2022.

 

Application is being made for 83,256 new Ordinary Shares to be admitted to
trading on the Main Market of the London Stock Exchange which is expected to
be on or around 15 September 2023. These shares rank pari passu with the
existing Ordinary Shares of the Company.

 

Following the issue of these shares, the Company's issued ordinary share
capital shall consist of 5,003,275 Ordinary Shares. The figure of 5,003,275
represents the total voting rights in the Company and should be used by
shareholders as the denominator for the calculation by which they can
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the Financial Conduct Authority's
Disclosure Guidance & Transparency Rules.

 

Brad Taylor, Chief Executive Officer of Iconic Labs, commented:

 

"We are pleased to announce the allotment of shares to the Unsecured Creditors
satisfies the final condition to bring the CVA to a successful conclusion.
Once the CVA is discharged, Iconic will be well positioned to focus on its
business goals. The Board remains committed to delivering value to our
shareholders and stakeholders alike."

 

- Ends -

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

For any further information or enquiries please contact:

 

 Iconic Labs                            Tel: +44 (0) 7462 156238

 Brad Taylor, Chief Executive Officer   ir@iconiclabs.co.uk
 Novum Securities Limited               Tel: +44 (0) 20 7399 9400

 David Coffman / Daniel Harris
 Yellow Jersey PR                       Tel: +44 (0) 20 3004 9512

 Sarah Hollins                          iconic@yellowjerseypr.com

 Annabelle Wills

 Bessie Elliot

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRUUSBRORUKARR